$3.67
-0.01-0.27%
At close: -
$3.67
0.000.00%
After Hours: 5:38 PM EDT
Revance Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Revance Therapeutics using advanced sorting and filters.
Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Q3 | 2024-11-07 | $-0.37 | $-0.38 | 2.63 % |
Q2 | 2024-08-08 | $-0.36 | $-0.53 | 32.1 % |
Q1 | 2024-05-09 | $-0.54 | $-0.75 | 28.0 % |
Q4 | 2024-02-28 | $-0.62 | $-0.72 | 13.9 % |
Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Q3 | 2024-11-07 | $59.88M | $68.20M | -12.2 % |
Q2 | 2024-08-08 | $65.39M | $66.06M | -1.02 % |
Q1 | 2024-05-09 | $51.94M | $56.63M | -8.29 % |
Q4 | 2024-02-28 | $69.80M | $62.63M | 11.5 % |
Revance Therapeutics (RVNC) is scheduled to report earnings on February 26, 2025. The last reported earnings were for reported on November 7, 2024 for Q3.
The Actual EPS was $-0.37, which beat the estimate of $-0.38.
The Actual Revenue was $59.9M, which missed the estimate of $68.2M.
Browse earnings estimates, EPS, and revenue on all stocks.